These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 3622309)

  • 41. A selective ACAT-1 inhibitor, K-604, suppresses fatty streak lesions in fat-fed hamsters without affecting plasma cholesterol levels.
    Ikenoya M; Yoshinaka Y; Kobayashi H; Kawamine K; Shibuya K; Sato F; Sawanobori K; Watanabe T; Miyazaki A
    Atherosclerosis; 2007 Apr; 191(2):290-7. PubMed ID: 16820149
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Acyl-coenzyme A:cholesterol acyltransferase inhibitor, avasimibe, stimulates bile acid synthesis and cholesterol 7alpha-hydroxylase in cultured rat hepatocytes and in vivo in the rat.
    Post SM; Zoeteweij JP; Bos MH; de Wit EC; Havinga R; Kuipers F; Princen HM
    Hepatology; 1999 Aug; 30(2):491-500. PubMed ID: 10421659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of the antithrombotic drug suloctidil on low density lipoprotein processing and cholesterol metabolism in cultured human fibroblasts.
    Mazière C; Mazière JC; Houtia NE; Lauga J; Polonovski J
    J Clin Chem Clin Biochem; 1988 Jan; 26(1):3-6. PubMed ID: 2836546
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulatory effect of several cerebral circulatory drugs in man, with special reference to aminophylline, papaverine, cyclandelate, vincamine, prostaglandin E1 and isoxsuprine.
    Miyazaki M
    Jpn Circ J; 1978 Apr; 42(4):433-40. PubMed ID: 702768
    [No Abstract]   [Full Text] [Related]  

  • 45. Influence of trapidil and derivatives on cholesterol synthesis and esterification in cultured cells.
    Beitz J; Corsini A; Bellosta S; Bernini F; Fumagalli R; Mest HJ; Paoletti R
    Pharmacol Res; 1991 Oct; 24(3):235-42. PubMed ID: 1956868
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Use of a product of esterification of mandelic acid with 3,5,5-triethylcyclohexanol (cyclospasmol) in the treatment of peripheral arteriopathy].
    STARACE G; NOFERI A; PADULA R
    Gazz Med Ital; 1960 Apr; 119():133-6. PubMed ID: 13833815
    [No Abstract]   [Full Text] [Related]  

  • 47. Biochemical and genetic studies of the apoprotein E secreted by mouse macrophages and human monocytes.
    Basu SK; Ho YK; Brown MS; Bilheimer DW; Anderson RG; Goldstein JL
    J Biol Chem; 1982 Aug; 257(16):9788-95. PubMed ID: 6286633
    [No Abstract]   [Full Text] [Related]  

  • 48. Simultaneous determination of cyclandelate and its metabolite in human plasma by capillary column gas-liquid chromatography.
    Andermann G; Dietz M
    J Chromatogr; 1981 May; 223(2):365-70. PubMed ID: 7251791
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Investigation on spasmolytics. VII. The metabolism of 3,5,5-trimethylcyclohexylmandelate (cyclandelate). II.
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Jun; 12():632-5. PubMed ID: 13890671
    [No Abstract]   [Full Text] [Related]  

  • 50. Investigation on spasmolytics. VIII. The metabolism of 3,5,5-trimethylcyclohexyl mandelate (Cyclandelate) (III).
    ERNSTING MJ; REKKER RF; TERSTEEGE HM; NAUTA WT
    Arzneimittelforschung; 1962 Jul; 12():691-4. PubMed ID: 13890672
    [No Abstract]   [Full Text] [Related]  

  • 51. Specific effects of cyclandelate on memory.
    Ananth J
    Drugs; 1987; 33 Suppl 2():97-102. PubMed ID: 3622311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of cyclandelate on dementia.
    Westreich G; Alter M; Lundgren S
    Stroke; 1975; 6(5):535-8. PubMed ID: 1101457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of cyclandelate in depressed and demented patients: a controlled study in psychogeriatric patients.
    Davies G; Hamilton S; Hendrickson E; Levy R; Post F
    Age Ageing; 1977 Aug; 6(3):156-62. PubMed ID: 331919
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Perceived efficacy of cyclandelate in the treatment of cochleovestibular and retinal disturbances related to cerebrovascular insufficiency. A study in general practice comprising 2772 patients.
    Memin Y
    Drugs; 1987; 33 Suppl 2():120-4. PubMed ID: 3497796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cyclandelate in the treatment of senility: a controlled study.
    Capote B; Parikh N
    J Am Geriatr Soc; 1978 Aug; 26(8):360-2. PubMed ID: 353121
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cyclandelate in the treatment of cerebral arteriosclerosis.
    Hall P
    J Am Geriatr Soc; 1976 Jan; 24(1):41-5. PubMed ID: 811704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cyclandelate in the treatment of vertigo of circulatory origin. A study in general practice.
    de Halleux F
    Drugs; 1987; 33 Suppl 2():114-9. PubMed ID: 3622305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Effects of cyclandelate on the CNS--a double-blind, placebo-controlled study of healthy subjects].
    Dimpfel W; Netter P; Spüler M; Wedekind W
    Klin Wochenschr; 1991 May; 69(7):313-9. PubMed ID: 2067317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclandelate in the treatment of senile mental changes: a double-blind evaluation.
    Rao DB; Georgiev EL; Paul PD; Guzman AB
    J Am Geriatr Soc; 1977 Dec; 25(12):548-51. PubMed ID: 336670
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cyclandelate in diabetic radiculoneuropathy.
    van der Drift JH
    Ann Neurol; 1980 Apr; 7(4):388. PubMed ID: 7377764
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.